Straight lines suddenly look bent, there’s a dark or distorted patch in the center of your vision, and it got worse over days, not months. That’s the alarm bell for choroidal neovascularization — abnormal blood vessels growing under the retina that leak and bleed. Before anti-VEGF drugs existed, this was a one-way ticket to legal blindness. The AAO notes these injections have transformed outcomes, preventing severe vision loss in most treated patients.
But “transformed” doesn’t mean cheap or one-and-done. Here’s what ongoing treatment actually costs.
What CNV Is and Why It Happens
Choroidal neovascularization (CNV) is the growth of fragile new blood vessels from the choroid (the eye’s vascular layer) up through the retina. Those vessels leak fluid and blood, scarring the macula and destroying central vision if untreated.
| Underlying Cause | Who It Affects |
|---|---|
| Wet macular degeneration | Adults over 50 (most common) |
| High myopia (myopic CNV) | Severely nearsighted, often younger |
| Ocular histoplasmosis | Exposure in certain US regions |
| Trauma/angioid streaks | Variable |
Whatever the cause, the leaking vessels are the enemy, and anti-VEGF injections are the answer.
Diagnostic Costs
Diagnosis and ongoing tracking lean heavily on imaging.
| Diagnostic Step | Cost Without Insurance |
|---|---|
| Retina specialist visit | $250–$450 |
| OCT (retinal scan) | $75–$200 |
| Fluorescein angiography | $300–$600 |
| OCT angiography | $150–$400 |
You’ll get repeat OCT scans at most injection visits to see whether the fluid is responding.
The Real Cost: Anti-VEGF Injections
This is where the money is, because CNV is a chronic condition managed with repeat injections, not a single fix.
CNV treatment is a marathon, not a sprint, and the drug you use drives the cost. Bevacizumab (Avastin) is the budget workhorse at $200–$300 a shot and works well for many patients. Branded drugs like aflibercept (Eylea) and ranibizumab (Lucentis) cost $1,800–$2,000 each but may stretch the time between injections or control stubborn cases better. Over a year of monthly-to-quarterly injections, you’re looking at $5,000–$15,000+ in drug-and-visit costs — almost all covered by insurance or Medicare, which is why out-of-pocket stays manageable.
| Drug | Cost Per Injection | Notes |
|---|---|---|
| Bevacizumab (Avastin) | $200–$300 | Off-label, widely used, low cost |
| Ranibizumab (Lucentis) | $1,200–$1,800 | FDA-approved for CNV |
| Aflibercept (Eylea) | $1,800–$2,000 | Often longer interval |
| Faricimab (Vabysmo) | $1,800–$2,200 | Newer, extended dosing |
The treatment is identical in mechanism to the broader category of anti-VEGF injection therapy used across retinal diseases. Many patients start with monthly injections, then move to a “treat and extend” schedule that stretches the interval as the eye stabilizes.
Annual Cost Math
A patient on monthly bevacizumab for a year runs roughly $5,000–$7,000 in drug and visit costs. Switch to a branded drug every other month and the gross cost can top $15,000 a year. With Medicare or commercial insurance, your actual out-of-pocket is usually a small fraction — often $0–$3,000 a year depending on your plan and any copay assistance.
Do not skip or stretch injections on your own to save money. CNV that’s undertreated bleeds and scars the macula permanently, and once the scar forms, no injection brings that central vision back. If cost is a barrier, ask your retina specialist about switching to bevacizumab and about manufacturer copay assistance programs for branded drugs. New, sudden distortion in your vision between appointments means call the office that day — fresh bleeds respond far better than old ones.
How to Keep Costs Down
Ask whether bevacizumab is appropriate for your case — it’s a fraction of the branded price and effective for many patients. Use a home Amsler grid daily to catch flares early, when fewer extra injections are needed. Because CNV bills to medical insurance and not vision insurance, confirm your specialist is in-network, and look into copay assistance if you’re on a branded drug. Regular eye exam visits help catch CNV early, before the scar forms.
Bottom Line
CNV treatment means ongoing anti-VEGF injections costing $200–$2,000 each, adding up to $5,000–$15,000+ a year in gross drug-and-visit costs — but insurance and Medicare cover the bulk, keeping out-of-pocket much lower. Per the AAO, these injections prevent severe vision loss in most treated patients, turning what used to mean blindness into a manageable chronic condition. The cheapest mistake to avoid is skipping shots, because lost central vision doesn’t come back.
Frequently Asked Questions
Wet macular degeneration is the most common cause of choroidal neovascularization (CNV), but CNV can also come from high myopia, ocular histoplasmosis, or trauma. Either way, the abnormal blood vessels are treated the same way — with anti-VEGF injections. The AAO notes anti-VEGF therapy has transformed outcomes, preventing severe vision loss in the majority of treated patients who previously would have gone blind.
Each anti-VEGF injection runs $200–$300 for bevacizumab (Avastin) up to $1,800–$2,000 for branded drugs like aflibercept (Eylea) or ranibizumab (Lucentis). Patients often need monthly injections at first, then every 1–3 months ongoing, which adds up to $5,000–$15,000+ per year. Insurance and Medicare cover them, so out-of-pocket is usually a fraction of that.
Yes. CNV is a medical condition, so injections, imaging, and visits bill to medical insurance or Medicare, not your vision plan. The cheaper drug bevacizumab keeps Medicare copays low, while branded drugs cost more but may be chosen for tougher cases. Vision plans like VSP don't cover any CNV treatment.